Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients.
Cortical thickness
GBA
Glucocerebrosidase gene
Magnetic resonance imaging
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
14
04
2021
accepted:
11
07
2021
revised:
23
06
2021
pubmed:
24
7
2021
medline:
23
2
2022
entrez:
23
7
2021
Statut:
ppublish
Résumé
To study the longitudinal disease course of Parkinson's disease (PD) patients with glucocerebrosidase (GBA) mutation (GBA-positive) compared to PD non-carriers (GBA-negative) along a 5-year follow-up, evaluating changes in clinical and cognitive outcomes, cortical thickness, and gray-matter (GM) volumes. Ten GBA-positive and 20 GBA-negative PD patients underwent clinical, neuropsychological, and MRI assessments (cortical thickness and subcortical, hippocampal, and amygdala volumes) at study entry and once a year for 5 years. At baseline and at the last visit, each group of patients was compared with 22 age-matched healthy controls. Clinical, cognitive, and MRI features were compared between groups at baseline and over time. At baseline, GBA-positive and GBA-negative PD patients had similar clinical and cognitive profiles. Compared to GBA-negative and controls, GBA-positive patients showed cortical thinning of left temporal, parietal, and occipital gyri. Over time, compared to GBA-negative, GBA-positive PD patients progressed significantly in motor and cognitive symptoms, and showed a greater pattern of cortical thinning of posterior regions, and frontal and orbito-frontal cortices. After 5 years, compared to controls, GBA-negative PD patients showed a pattern of cortical thinning similar to that showed by GBA-positive cases at baseline. The two groups of patients showed similar patterns of subcortical, hippocampal, and amygdala volume loss over time. Compared to GBA-negative PD, GBA-positive patients experienced a more rapid motor and cognitive decline together with a greater, earlier and faster cortical thinning. Cortical thickness measures may be a useful tool for monitoring and predicting PD progression in accordance with the genetic background.
Identifiants
pubmed: 34297177
doi: 10.1007/s00415-021-10713-4
pii: 10.1007/s00415-021-10713-4
doi:
Substances chimiques
Glucosylceramidase
EC 3.2.1.45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1485-1500Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : #175090
Organisme : Ministero della Salute
ID : RF-2018-12366746
Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Romero R, Ramanathan A, Yuen T, Bhowmik D, Mathew M, Munshi LB et al (2019) Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Proc Natl Acad Sci USA 116(11):5086–5095
doi: 10.1073/pnas.1818411116
Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372(9645):1263–1271
doi: 10.1016/S0140-6736(08)61522-6
Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89(9):691–694
doi: 10.1093/qjmed/89.9.691
Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73(4):313–321
doi: 10.1006/mgme.2001.3201
Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79(2):104–109
doi: 10.1016/S1096-7192(03)00071-4
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361(17):1651–1661
doi: 10.1056/NEJMoa0901281
Aflaki E, Westbroek W, Sidransky E (2017) The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. Neuron 93(4):737–746
doi: 10.1016/j.neuron.2017.01.018
Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W et al (2015) GBA-associated Parkinson’s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30(3):407–411
doi: 10.1002/mds.26071
Zhang Y, Shu L, Zhou X, Pan H, Xu Q, Guo J et al (2018) A meta-analysis of GBA-related clinical symptoms in Parkinson’s disease. Parkinsons Dis 2018:3136415
pubmed: 30363648
pmcid: 6180987
Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S et al (2016) Survival and dementia in GBA-associated Parkinson’s disease: the mutation matters. Ann Neurol 80(5):662–673
doi: 10.1002/ana.24777
Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T et al (2011) GBA-associated PD presents with nonmotor characteristics. Neurology 77(3):276–280
doi: 10.1212/WNL.0b013e318225ab77
Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T et al (2020) Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease. J Neurol Neurosurg Psychiatry 91(7):695–702
doi: 10.1136/jnnp-2020-322857
Agosta F, Kostic VS, Davidovic K, Kresojevic N, Sarro L, Svetel M et al (2013) White matter abnormalities in Parkinson’s disease patients with glucocerebrosidase gene mutations. Mov Disord 28(6):772–778
doi: 10.1002/mds.25397
Thaler A, Kliper E, Maidan I, Herman T, Rosenberg-Katz K, Bregman N et al (2018) Cerebral imaging markers of GBA and LRRK2 related Parkinson’s disease and their first-degree unaffected relatives. Brain Topogr 31(6):1029–1036
doi: 10.1007/s10548-018-0653-8
Kono S, Ouchi Y, Terada T, Ida H, Suzuki M, Miyajima H (2010) Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. Mov Disord 25(12):1823–1829
doi: 10.1002/mds.23213
Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S et al (2010) Gaucher disease ascertained through a Parkinson’s center: imaging and clinical characterization. Mov Disord 25(10):1364–1372
doi: 10.1002/mds.23046
Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jager C, et al (2020) GBA variants in Parkinson's disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Mov Disord 35(12):2201–2210
doi: 10.1002/mds.28225
Filippi M, Canu E, Donzuso G, Stojkovic T, Basaia S, Stankovic I et al (2020) Tracking cortical changes throughout cognitive decline in Parkinson’s disease. Mov Disord 35(11):1987–1998
doi: 10.1002/mds.28228
Filippi M, Sarasso E, Piramide N, Stojkovic T, Stankovic I, Basaia S et al (2020) Progressive brain atrophy and clinical evolution in Parkinson’s disease. Neuroimage Clin 28:102374
doi: 10.1016/j.nicl.2020.102374
Filippi M, Basaia S, Sarasso E, Stojkovic T, Stankovic I, Fontana A et al (2020) Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease. Mol Psychiatry. https://doi.org/10.1038/s41380-020-0770-0
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
doi: 10.1136/jnnp.55.3.181
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 ((quiz 837))
doi: 10.1002/mds.21507
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653
doi: 10.1002/mds.23429
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442
doi: 10.1212/WNL.17.5.427
Movement Disorder Society Task Force on Rating Scales for Parkinson’s D (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738–750
doi: 10.1002/mds.10473
Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923
doi: 10.1002/mds.20844
Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22(16):2386–2393
doi: 10.1002/mds.21740
Kumar KR, Ramirez A, Gobel A, Kresojevic N, Svetel M, Lohmann K et al (2013) Glucocerebrosidase mutations in a Serbian Parkinson’s disease population. Eur J Neurol 20(2):402–405
doi: 10.1111/j.1468-1331.2012.03817.x
Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 97(20):11050–11055
doi: 10.1073/pnas.200033797
Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21(12):2042–2051
doi: 10.1002/mds.21065
Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T et al (2013) Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain 136(Pt 2):392–399
doi: 10.1093/brain/aws318
Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M et al (2012) Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 78(18):1434–1440
doi: 10.1212/WNL.0b013e318253d54b
Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM et al (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Mov Disord 31(1):95–102
doi: 10.1002/mds.26359
Lewis MM, Du G, Lee EY, Nasralah Z, Sterling NW, Zhang L et al (2016) The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions. J Neurol 263(1):68–75
doi: 10.1007/s00415-015-7929-7
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW et al (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969
doi: 10.1093/brain/awp245
Pal G, Robertson E, O’Keefe J, Hall D (2016) The Neuropsychiatric and motor profile of GBA-associated Parkinson’s disease: a review. Mov Disord Clin Pract 3(1):4–8
doi: 10.1002/mdc3.12229
Avenali M, Toffoli M, Mullin S, McNeil A, Hughes DA, Mehta A et al (2019) Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry 90(10):1091–1097
doi: 10.1136/jnnp-2019-320394
Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T et al (2017) A “dose” effect of mutations in the GBA gene on Parkinson’s disease phenotype. Parkinsonism Relat Disord 36:47–51
doi: 10.1016/j.parkreldis.2016.12.014
Riboldi GM, Di Fonzo AB (2019) GBA, Gaucher disease, and Parkinson's disease: from genetic to clinic to new therapeutic approaches. Cells 8(4):364